Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Sinobiopharma Inc. (SNBP.OB) Partners with Xianfeng Pharmaceuticals to Co-produce and Market Two Biopharm Technologies

Biopharmaceutical company Sinobiopharma Inc. focuses on anesthesia-assisted agents and cardiovascular drugs. The company today announced an agreement with Anhui Xianfeng Pharmaceuticals Co. Ltd (Xianfeng) to manufacture and co-market Clindamycin and L-alanyl-L-glutamine.

Clindamycin is an antibiotic used to treat anaerobic bacterial infections, some protozoal diseases (such as malaria), and is also used as a topical acne treatment cream; parenteral nutrition product L-alanyl-L-glutamine is prescribed for patients after surgery.

Sinobiopharma owns the drug certificates, drug registration approval documents and production technologies of the two products.

Per the agreement, Xianfeng will pay Sinobiopharma to obtain access to the technologies. Xianfeng is equipped with manufacturing facilities that will lower production costs. In accordance, Sinobiopharma will pay Xianfeng for manufacturing the drugs, and the companies will jointly market the products.

“Xianfeng has the GMP-certified facilities for the production of Clindamycin and L-alanyl-L-glutamine and is a strong marketing partner,” Dr. Lequn Lee Huang, chairman and CEO of Sinobiopharma stated in the press release. “We expect production to start later this year and are confident this cooperation will help fuel the continued growth of Sinobiopharma.”

The companies have not yet released financial terms of the agreement.

For more information

Please see disclaimer on QualityStocks website:

Disclosure: no positions